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FK 506 is a macrolide with potent immunosuppressive 
effects. Its immunosuppressive property has been 
documented in both in vitro! lymphocyte proliferation 
studies and in vivo studies. FK 506 treatment significantly 
prolongs graft survival in rats receiving heterotopic heart 
transplants. dogs receiving kidneys or livers. and baboons 
receiving kidney transplants.2 Currently, FK 506 is under-
going clinical trials at the University of Pittsburgh. This 
document provides a summary of the biopharmaceutical 
aspects and the pharmacokinetics of the drug in animals 
and humans. 
CHEMICAL AND PHYSICOCHEMICAL PROPERTIES 
FK 506 belongs to a group of chemicals referred to as the 
macrolides. Macrolides are macrocyclic lactones contain-
ing keto and hydroxyl groups. Other macrolides that are 
presently known include erythromycin. oleandomycin. 
spiromycin. carbomycin. josamycin. leucomycin. tylosin. 
and rapamycin. In addition to FK 506. rapamycin has also 
been reported to possess some immunosuppressive activ-
ity. 
FK 506 has a molecular weight of 822. It is highly 
lipophilic in nature. It is very soluble in methanol. chloro-
form. acetone. ethyl acetate. ethanol. and propylene gly-
col. It is moderately soluble in polyethylene glycol and 
ether. slightly soluble in olive oil and glycerin. and poorly 
soluble in water and hexane. J FK 506 is stable in solid state 
and in the presence of very dilute HCl. It is degraded into 
mUltiple components in the presence of 6 N or concen-
trated HCI. Methanolic solution of FK 506 is stable for 
several months at - 20°C. 
DOSAGE FORM OF FK 506 
Preclinical pharmacokinetic studies have been carried out 
with intravenous. oral. and intramuscular dosage forms of 
FK 506. Clinical studies have used the intravenous and 
oral dosage forms of FK 506. 
The intravenous dosage form of FK is available as a 10 
mg/ml solution. This solution contains FK 506. polyoxy-
ethylated hydrogenated castor oil (HCO-60. a surfactant). 
and alcohol. The intravenous preparation must be diluted 
with saline or dextrose and administered as an infusion for 
I or 2 hours in humans. Diluted intravenous FK 506 
solution has been used for rapid infusion (less than 30 
seconds) in animal studies. Intravenous FK 506 in saline or 
dextrose is stable: more than 90% of the dose is available 
to patients from a dextrose solution stored in glass con-
tainers for 24 hours. while greater than 10% of the drug is 
adsorbed onto plastic minibags within 6 hours. 
The oral dosage form is a 20% solid dispersion of FK 506 
in hydroxy propyl methyl cellulose and HCO-60. This 
dispersion is administered in a hard gelatin capSUle. The 
intramuscular dosage form used in animal studies contains 
27% of FK 506 in mannitol and HCO-60. This is normally 
suspended in water or saline and is administered as a 
suspension. 
DRUG ANALYSIS 
In clinical studies and in studies involving dogs and rats. 
FK 506 concentrations were measured by a monoclonal 
antibody-based ELISA as described elsewhere in this 
issue.4 FK 506 concentrations in baboon studies and in rat 
tissues were measured by a polyclonal antibody-based 
ELISA. 
PRECLINICAL STUDIES 
Intravenous Kinetics and Absorption 
Dogs. In the studies reported here. the plasma is 
separated from blood sample at 3rC. Following intrave-
nous administration (0.2 mg/kg). the concentration of FK 
506 declines very rapidly (Fig I). This corresponds to the 
distribution of FK 506 outside the vascular system. Once 
postdistribution equilibrium is established. the FK 506 
concentrations decline slowly over the rest of the dosing 
interval. This primarily indicates elimination of the drug 
from the central compartment and redistribution of the 
drug from the extravascular compartments. The mean 
terminal disposition half-life of FK 506 is 10.3 hours. with 
a range of9.0 to 13.2 hours. The mean plasma clearance is 
2.325 mUmin. with a range of 1.943 to 3.125 mUmin. This 
value is greater than the expected hepatic blood flow in 
dogs. suggesting possible extrahepatic metabolism of the 
drug. The high clearance also indicates that following oral 
administration. FK 506 is expected to undergo significant 
first-pass metabolism. 
Following oral administration (I mg/kg). the drug is 
rapidly absorbed as indicated: a very short lime is required 
(I to 2 hours) for achieving peak plasma concentrations. 
Peak plasma concentrations range from 1.9 ng/ml to 4.9 
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Fig 1. Plasma concentration versus time profile after intravenous 
administration of FK 506 (0.2 mgJkg) to dogs. 
ng/ml, with a mean value of2.8 ng/ml. The mean half-life is 
7 hours, with a range of 5.6 to 7.9 hours. The absolute oral 
bioavailability is calculated to be 9%. with a range of 5 to 
12%. In some dogs, secondary peaks are observed in the 
plasma concentration versus time curves. This is likely to 
be related to the poor solubility of FK 506 and the 
consequent precipitation. redissolution, and absorption of 
the drug after oral administration. The absence of any 
significant amount of the drug in the bile supports this 
hypothesis. 
Following intramuscular administration. FK 506 is ab-
sorbed very slowly and erratically. Steady-state concen-
trations are reached in 4 to 12 hours and the concentrations 
are maintained for at least 24 hours.s 
Baboons. In this study, the plasma is separated from 
blood sample at 24°C. Single oral dose administration of 
FK 506 (10 mglkg) to baboons (n = 4) results in a peak 
plasma concentration of 8.1 + 1.0 ng/ml. These concen-
trations are reached in 3.8 ± 1.4 hours after oral adminis-
tration. The half-life of FK is 9.6 ± 2.0 hours. 
Rats. FK 506 is absorbed rapidly after oral administra-
tion to rats. The presence of large amounts of radioactivity 
in the alimentary canal of bile duct cannulated rats follow-
ing oral administration of radioactive FK 506 indicates 
incomplete absorption of the drug from the gut (Internal 
Research Report. Fujisawa Pharmaceuticals Co Ltd, Os-
aka. Japan). The half-life of FK 506 in rats appears to be 
less than 3 hours. 
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Fig 2. Tissue concentrations of FK 506 in rats after 14 days of 
intramuscular treatment (1.28 mgJkgJd). 
Distribution 
Distribution of FK 506 in various organs in the body is 
determined after intramuscular administration of 1.28 mg/ 
kg for 14 days (Fig 2). This study indicates that the 
concentrations are in the following order: lungs> spleen> 
heart> kidney> pancreas> liver = plasma (24°C). The 
mean concentration in the lung tissue is nearly eight times 
that present in the plasma. 
Elimination 
The elimination of FK 506 after intravenous or oral admin-
istration has been studied in rats (Fig 3). Studies using 
radioactive FK 506 ('4C) indicate that about 11% of the 
radioactive material administered intravenously is ex-
creted in the urine, while nearly 80% of the radioactivity is 
excreted in the bile and 8% is in the feces within 48 hours 
(Internal Research Report, Fujisawa Pharmaceutical Co 
Ltd). Following oral administration, about 4% of the 
radioactive material is excreted in urine. 34% is in the 
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Fig 3. Percent of the dose excreted in urine. feces, and bile 
within 48 hours after intravenous and oral administration to bile 
duct cannulated rats. 
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feces. and 19% appears in the bile. Less than 1% of the 
dose is excreted in the urine or bile as unchanged drug 
within 48 hours in rats and in dogs. indicating complete 
metabolism of the drug. 
Drug Interactions 
Chronic intramuscular administration of FK S06 (1.28 
mglkg) decreases cytochrome P-4S0 concentrations (0.9 ± 
0.92 to 0.68 ± 0.03 N moUmg protein) and decreases the 
activity of ethylmorphine N-demethylase (19.3 ± 2.7 to 6.4 
± 1.8 N mol HCHO/minimg protein) in male Wistar rats.5 
In Wistar rats. FK S06 (I mglkg/d for 4 days) increases the 
trough concentration of CyA after a single intravenous 
bolus dose of 4 mglkg (test animals. 643 ± 13S nglml: 
control animals. 368 ± 99 nglmi). These observations 
indicate that FK S06 may inhibit the metabolism of other 
coadministered drugs. 
Drug Accumulation 
Chronic administration of a drug more often than once in 
six half-lives is expected to result in accumulation of the 
drug. Based on trough concentrations and measurements 
of area under plasma concentration (AUC). it can be 
concluded that in baboons and dogs, FK S06 accumulates 
in the body after chronic oral administration (Internal 
Research Report. Fujisawa Pharmaceuticals Co Ltd). 
Dose and Time Dependency in Kinetics 
In dogs. the AUC values after a single oral dose increase in 
proportion to the dose administered. up to a dose of 3.2 
mg/kg. At a dose of 4 mglkg, there is a disproportionate 
increase in the AUC. indicating some nonlinearity in the 
kinetic processes involved. 5 In baboons. there is no evi-
dence of any nonlinearity up to a single oral dose of 10 
mglkg (Internal Research Report. Fujisawa Pharmaceuti-
cal Co Ltd). 
FK S06 kinetics do not change after chronic intramus-
cular treatment in baboons. as indicated by similar half-
lives (9.6 ± 2 hours on day I and 9.S ± I hour on day 28) 
and time to reach peak plasma concentrations (3.8 ± 1.4 
hours on day I versus 3.3 ± 1.0 hour on day 28) after oral 
administration on day I and 28. 
CLINICAL STUDIES 
Intravenous Administration and Absorption 
In all human kinetic studies. plasma is separated from 
blood samples at 37°C. Following intravenous infusion 
(O.IS mg/kg over 2 hours). FK S06 concentrations decline 
rapidly (Fig 4). Peak concentrations at the end of infusion 
range from 10 to 24 nglm!. Once the distribution equilib-
rium is reached. the drug concentrations decline slowly 
over the next 24 hours. The half-life ranges from S.S to 16.6 
hours. with a mean of 8.7 hours. The plasma clearance 
averages 143 LIh. ranging from 87 to 269 LIh. This indi-
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Fig 4. Plasma concentration of FK 506 versus time curve after 
intravenous infusion (9 mg over 2 hours) in two patients. 
cates that FK S06 is a high-clearance drug. The mean 
volume of distribution is 1.342 L. suggesting extensive 
distribution of the drug in the body. 
Following oral administration. FK S06 is poorly. errati-
cally. and incompletely absorbed (Fig S). In some patients. 
the drug seems to be absorbed continuously over most of 
the dosing interval. An oral dose ofO.IS mg/kg results in a 
peak plasma concentration of 0.4 to 3.7 nglm!. The time to 
reach peak concentration varies from I to 4 hours. The 
mean bioavailability calculated is 27%. 
Distribution 
The large volume of distribution indicates extensive ex-
travascular uptake of FK S06. Even though FK 506 
concentrations have not been measured in any human 
tissues. based on animal studies. high concentrations of 
FK S06 are expected in lung. kidney. heart. and spleen. At 
a concentration of 2S0 nglml. the blood to plasma concen-
tration of FK 506 is I.S. indicating uptake into red blood 
cells. Within plasma. FK S06 primarily resides in the 
lipoprotein-deficient fraction. As shown in Table 1. only 
24% of the FK S06 is taken up in the various lipoprotein 
fractions. as compared with nearly 77% in the case ofCyA. 
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Fig 5. Plasma concentration of FK 506 versus time curve after oral administration of 9 mg of FK 506 to four patients. 
The concentration of FK 506 in plasma is dependent on 
the temperature at which the blood is separated. The 
concentration in the plasma separated at 37°C is nearly 
twice that separated at 24°C (Fig 6). Attention must be paid 
to the proper sample preparation technique. 
In one patient. simultaneous blood and cerebrospinal 
fluid samples were obtained. and it was found that when 
the plasma concentration was 3.3 nglml. the concentration 
in the cerebrospinal fluid was <0.1 ng/mi. 
Elimination 
Less than I % of the intravenous or oral dose of FK 506 
appears in the urine. This indicates the drug to be com-
pletely metabolized prior to elimination from the body. 
The concentration of FK 506 in dialysis fluid is less than 
the detection limits of the assay used. Since the drug is 
completely metabolized. it is highly lipid-soluble. has a 
high volume of distribution. and. with a molecular weight 
Table 1. Distribution of FK 506 In Plasma 
FK 506 E%~ CyA(%) 
Very-low-denSity lipoprotein 1.9 10 
Low-density lipoprotein 2.7 32 
High-density lipoprotein 19.6 37 
LJpoprotein-deflcient tractIOn 76.1 23 
of 822. it is not expected to be dialyzable. These observa-
tions indicate that dosing regimen changes may not be 
necessary in patients with renal failure or in patients 
undergoing dialysis. However. the kinetics of FK 506 are 
expected to be altered in patients with liver dysfunction. 
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The metabolic pathways of FK 506 have not been 
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Fig 6. Temperature-dependent plasma FK 506 concentration in 
patients. D. BlOOd sample separated at 24°C; D. blOOd sample 
separated at 37"C. 
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completely characterized. It is expected to undergo 0-
de methylation and possible conjugation. 
Dose and Time Dependency 
Preliminary data indicate that at dose levels of 0.05 and 
0.15 mglkg IV. there is no dose dependency in the AVC in 
patients. Time dependency in FK 506 kinetics has not been 
completely characterized. 
Drug Interaction 
In patients receiving FK 506. the half-life of Cy A is 
prolonged. The half-life of CyA in patients not receiving 
FK 506 is nonnally 6 to 15 hours. In patients on FK 506 
who have a normal bilirubin concentration. the half-life of 
Cy A after oral administration calculated from the concen-
trations based on fluorescent polarization immunoassay 
ranges from 26 to 74 hours. This indicates inhibition of 
CyA metabolism or potential alterations in CyA absorp-
tion by FK 506. 
Of the 17 incidences of methylprednisolone treatments. 
FK 506 plasma concentrations increased on \0 occasions. 
decreased on 5 occasions. and did not change on 2 occa-
sions. The potential effect of methylprednisolone on FK 
506 kinetics needs further study. 
Monitoring of FK 506 
The pharmacokinetics of FK 506 are variable among 
patients. and the absorption of the drug after oral admin-
istration is variable and incomplete. This indicates the 
need for monitoring the plasma concentrations of FK 506 
in patients to avoid potential rejection of the transplanted 
organ. Since the distribution of FK 506 in blood is temper-
ature-dependent. plasma must be separated at carefully 
controlled temperatures. In our preliminary observations. 
the trough concentrations of FK 506 range from <0.1 
nglml to nearly 5 nglml after an oral dose of 0.15 mglkgld. 
There is no specific side effect associated with higher 
trough concentrations. It appears that FK 506 may have a 
larger therapeutic index and. therefore. it may not be 
necessary to monitor the drug every day. 
DISCUSSION 
Prectinical 
FK 506 is poorly absorbed after oral administration and. 
therefore. a higher oral dose is required for achieving 
similar plasma concentrations when compared with an 
intravenous dose. It is extensively distributed in various 
tissues. and concentrations exceeding plasma concentra-
tions are observed in lung. spleen. heart. and kidney. FK 
506 is completely metabolized prior to elimination from the 
body. Based on the half-life of FK 506. a dosing interval of 
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Table 2. Phannacoklnetlc Propertle. of FK 506 
Absorption 
Rate: Rapid 
Extent: 27% 
Distribution 
Extensive tissue distribution 
Elimination 
High-clearance drug 
Completely metabolized 
Less than 1 % of the dose exaeted in unne 
Half-life: 8.7 hours 
Drug interactions 
FK 506 increases CyA concentration 
Potential for inhibition of metabolism of other drugs 
12 or 24 hours seems normally appropriate. FK 506 
accumulates in the body after chronic dosing. However. 
the kinetics of FK 506 do not change after chronic oral 
treatment. At single oral doses below 3.2 mglkg. the 
kinetics appear to be linear. FK 506 decreases the activity 
of hepatic drug metabolizing enzymes. Dosing regimen of 
some coadministered drugs may have to be reduced to 
prevent toxicity. 
Clinical 
The various pharmacokinetic properties of FK 506 are 
summarized in Table 2. FK 506 is poorly and incompletely 
absorbed after oral administration. The drug is extensively 
distributed in the body. FK 506 is a high-clearance drug 
and is eliminated by metabolism. From a pharmacokinetic 
basis. changes in FK 506 dosing regimen may not be 
necessary in patients with kidney failure and in patients on 
dialysis. but may be necessary in patients with hepatic 
dysfunction. Based on the half-life. a once- or twice-a-day 
regimen appears to be appropriate in humans. FK 506 
increases CyA concentrations and may affect the concen-
trations of other coadministered drugs. Since FK 506 is 
primarily eliminated by metabolism. its kinetics may be 
affected by other drugs. Monitoring of FK 506 concentra-
tions will help in optimizing therapy with this drug. 
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